ExpreS2ion announces financial results for the third quarter 2022
Hørsholm, Denmark, November 17, 2022 – ExpreS2ion Biotech Holding AB (“ExpreS2ion”) today announces its third quarter financial results for 2022. The report is available as an attachment and on ExpreS2ion's website (www.expres2ionbio.com). Below is a summary of the report.CEO Bent U. Frandsen comments “The vaccination of the first subject in the COVID-19 Phase III clinical trial for ABNCoV2 as a booster vaccine is a historic milestone for ExpreS[2]ion as a company, as this is the first time our ExpreS2 platform is being evaluated in a clinical Phase III trial. We are also seeing